201 related articles for article (PubMed ID: 34873959)
1. Biomarker-driven immunotherapy for precision medicine in prostate cancer.
Ottini A; Sepe P; Beninato T; Claps M; Guadalupi V; Verzoni E; Giannatempo P; Baciarello G; de Braud F; Procopio G
Per Med; 2022 Jan; 19(1):51-66. PubMed ID: 34873959
[TBL] [Abstract][Full Text] [Related]
2. Hypermutated tumours in the era of immunotherapy: The paradigm of personalised medicine.
Nebot-Bral L; Brandao D; Verlingue L; Rouleau E; Caron O; Despras E; El-Dakdouki Y; Champiat S; Aoufouchi S; Leary A; Marabelle A; Malka D; Chaput N; Kannouche PL
Eur J Cancer; 2017 Oct; 84():290-303. PubMed ID: 28846956
[TBL] [Abstract][Full Text] [Related]
3. Immune landscape of human prostate cancer: immune evasion mechanisms and biomarkers for personalized immunotherapy.
Bou-Dargham MJ; Sha L; Sang QA; Zhang J
BMC Cancer; 2020 Jun; 20(1):572. PubMed ID: 32552802
[TBL] [Abstract][Full Text] [Related]
4. Immunogenomic analyses associate immunological alterations with mismatch repair defects in prostate cancer.
Nava Rodrigues D; Rescigno P; Liu D; Yuan W; Carreira S; Lambros MB; Seed G; Mateo J; Riisnaes R; Mullane S; Margolis C; Miao D; Miranda S; Dolling D; Clarke M; Bertan C; Crespo M; Boysen G; Ferreira A; Sharp A; Figueiredo I; Keliher D; Aldubayan S; Burke KP; Sumanasuriya S; Fontes MS; Bianchini D; Zafeiriou Z; Teixeira Mendes LS; Mouw K; Schweizer MT; Pritchard CC; Salipante S; Taplin ME; Beltran H; Rubin MA; Cieslik M; Robinson D; Heath E; Schultz N; Armenia J; Abida W; Scher H; Lord C; D'Andrea A; Sawyers CL; Chinnaiyan AM; Alimonti A; Nelson PS; Drake CG; Van Allen EM; de Bono JS
J Clin Invest; 2018 Oct; 128(10):4441-4453. PubMed ID: 30179225
[TBL] [Abstract][Full Text] [Related]
5. Targeting DNA Repair Defects for Precision Medicine in Prostate Cancer.
Athie A; Arce-Gallego S; Gonzalez M; Morales-Barrera R; Suarez C; Casals Galobart T; Hernandez Viedma G; Carles J; Mateo J
Curr Oncol Rep; 2019 Mar; 21(5):42. PubMed ID: 30919167
[TBL] [Abstract][Full Text] [Related]
6. Utilizing precision medicine to modulate the prostate tumor microenvironment and enhance immunotherapy.
Olson B; Patnaik A
Urol Oncol; 2019 Aug; 37(8):535-542. PubMed ID: 30503851
[TBL] [Abstract][Full Text] [Related]
7. Optimizing cancer immunotherapy: Is it time for personalized predictive biomarkers?
Music M; Prassas I; Diamandis EP
Crit Rev Clin Lab Sci; 2018 Nov; 55(7):466-479. PubMed ID: 30277835
[TBL] [Abstract][Full Text] [Related]
8. Immune Checkpoint Inhibitors: A Promising Treatment Option for Metastatic Castration-Resistant Prostate Cancer?
Ruiz de Porras V; Pardo JC; Notario L; Etxaniz O; Font A
Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33946818
[TBL] [Abstract][Full Text] [Related]
9. Refining Immuno-Oncology Approaches in Metastatic Prostate Cancer: Transcending Current Limitations.
Wong RL; Yu EY
Curr Treat Options Oncol; 2021 Jan; 22(2):13. PubMed ID: 33433743
[TBL] [Abstract][Full Text] [Related]
10. Future directions for precision oncology in prostate cancer.
Mizuno K; Beltran H
Prostate; 2022 Aug; 82 Suppl 1(Suppl 1):S86-S96. PubMed ID: 35657153
[TBL] [Abstract][Full Text] [Related]
11. A PoleP286R mouse model of endometrial cancer recapitulates high mutational burden and immunotherapy response.
Li HD; Lu C; Zhang H; Hu Q; Zhang J; Cuevas IC; Sahoo SS; Aguilar M; Maurais EG; Zhang S; Wang X; Akbay EA; Li GM; Li B; Koduru P; Ly P; Fu YX; Castrillon DH
JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32699191
[TBL] [Abstract][Full Text] [Related]
12. Characterizing cyclin-dependent kinase 12(CDK12)-altered aggressive prostate cancer: a twelve-case series.
Iwasawa T; Kosaka T; Yasumizu Y; Hongo H; Yanai Y; Baba Y; Matsumoto K; Nakamura K; Nishihara H; Oya M
Int J Clin Oncol; 2022 Dec; 27(12):1867-1873. PubMed ID: 36271301
[TBL] [Abstract][Full Text] [Related]
13. Evolving Role of Immunotherapy in Metastatic Castration Refractory Prostate Cancer.
Rathi N; McFarland TR; Nussenzveig R; Agarwal N; Swami U
Drugs; 2021 Feb; 81(2):191-206. PubMed ID: 33369720
[TBL] [Abstract][Full Text] [Related]
14. Emerging Biomarker-Guided Therapies in Prostate Cancer.
Deluce JE; Cardenas L; Lalani AK; Maleki Vareki S; Fernandes R
Curr Oncol; 2022 Jul; 29(7):5054-5076. PubMed ID: 35877260
[TBL] [Abstract][Full Text] [Related]
15. The Value of Phenotypic Precision Medicine in Prostate Cancer.
Hawkey NM; Broderick A; George DJ; Sartor O; Armstrong AJ
Oncologist; 2023 Feb; 28(2):93-104. PubMed ID: 36200788
[TBL] [Abstract][Full Text] [Related]
16. Biological and therapeutic advances in the pursuit of effective immunotherapy for prostate cancer.
Hamid AA; Choudhury AD
Curr Opin Urol; 2020 Jan; 30(1):30-35. PubMed ID: 31609776
[TBL] [Abstract][Full Text] [Related]
17. Immunotherapy for Localized Prostate Cancer: The Next Frontier?
Patel D; McKay R; Parsons JK
Urol Clin North Am; 2020 Nov; 47(4):443-456. PubMed ID: 33008495
[TBL] [Abstract][Full Text] [Related]
18. Overcoming Immune Resistance With Radiation Therapy in Prostate Cancer.
Mulvey A; Muggeo-Bertin E; Berthold DR; Herrera FG
Front Immunol; 2022; 13():859785. PubMed ID: 35603186
[TBL] [Abstract][Full Text] [Related]
19. The Emergence of Immune-checkpoint Inhibitors in Colorectal Cancer Therapy.
Ghidini M; Fusco N; Salati M; Khakoo S; Tomasello G; Petrelli F; Trapani D; Petrillo A
Curr Drug Targets; 2021; 22(9):1021-1033. PubMed ID: 33563194
[TBL] [Abstract][Full Text] [Related]
20. Mismatch repair deficiency and clinical implications in prostate cancer.
Graham LS; Schweizer MT
Prostate; 2022 Aug; 82 Suppl 1():S37-S44. PubMed ID: 35358351
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
